PTEN and breast carcinoma: Characterization of a breast cancer patient with resistance to the PI3Kα inhibitor BYL719 displayed altered PI3K pathway dependence due to acquisition of multiple PTEN genetic alterations in distant metastases leading to PTEN protein loss [38].